Conference Reports for NATAP

Back

11th IAS Conference on HIV Science 18-21 July 2021     Biodegradable Polymeric Solid Implants for Ultra-Long-Acting Delivery of Single or Multiple Antiretroviral Drugs - (02/20/23)   COMORBIDITIES AND AGEING; IMMUNOMETABOLISM AND HIV PATHOGENESIS; TB & HIV; HIV Natural Controllers - Christina K. Psomas, MD (09/20/21)   Long-Acting Treatment: Cabotegravir/rilpivirine; Long-Acting Injectable PrEP HPTN 083, 084 - (08/31/21)   DECLINE IN HIV TESTING AND CHANGES IN POSITIVITY RATES DURING THE COVID-19 PANDEMIC - (08/30/21)   Lenacapavir; Islatravir, Doravirine at IAS 2021 - (08/30/21)   Co-morbidity and HIV: What Matters to Patients ? - IAS Symposium - Growing old with HIV: Co-morbidities and ageing (CME) - (08/25/21)   Epidemiological trends of hepatitis B morbidity and mortality in Greece, Italy, Portugal and Spain, 2000-2019: a systematic analysis from the Global Burden of Disease Study 2019 - (08/25/21)   HIV Immune Response to COVID - 2 studies: 1- Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV, 2 - SARS-Cov-2 immunity in COVID-19 convalescent individuals living with HIV: bulk immune profiling and SARS-CoV-2 specific humoral and cellular immune responses - (08/24/21)   Virological suppression in people living with HIV infection is not protective of subclinical atherosclerosis - (08/24/21)   Low rates of testing for sexually transmitted infections in an insured cohort of men and women living with HIV - (08/24/21)   Chronic morphine administration alters gut-brain homeostasis in SHIV infected rhesus macaques - (08/24/21)   Food insecurity is associated with increased immune activation in people living with HIV - (08/24/21)   Progress towards HCV elimination among HIV-positive men who have sex with men in Germany: a modeling analysis - (08/23/21)   The prevalence of hepatitis C virus (HCV) co-infection among people living with HIV (PLHIV) in Egypt: a cross-sectional study - (08/23/21)   Changes in Inflammation Scores Among People Living with HIV (PLWH) Under Different Antiretroviral Treatment (ART) Regimes - (08/23/21)   Baricitinib reduces macrophage-mediated inflammation in HIV infection - (08/23/21)   Ageing and renal insufficiency in persons living with and without HIV in AFRICOS - (08/23/21)   Daily Variations- HIV & Immunity, T-Cell Exhaustion in Vertically Acquired HIV-children/adolescents/adults - (08/23/21)   Circulating GDF15 levels [cellular stress] are associated with aging, risk of non-AIDS comorbidities and integrated HIV DNA in ART-treated people living with HIV - (08/23/21)   Stress & Aging, Sleep & Brain - (08/23/21)   Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open¬ label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy - (08/23/21)   Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Engaged in Transactional Sex - (08/23/21)   Dolutegravir + 3TC at IAS 2021 - (08/19/21)   Metabolics, Comorbidities & Aging at IAS 2021 - (08/13/21)   PSYCHOLOGICAL STRESS IS ASSOCIATED WITH CAROTID INFLAMMATION IN PERSONS WITH TREATED HIV INFECTION - (08/13/21)   Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' • between innate and adaptive immune cells in HIV controllers on ART - (08/11/21)   GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture - (08/11/21)   LOWER HIV RESERVOIR SIZE IN INDIVIDUALS WHO MAINTAIN HIGHER CD4+ T CELL COUNTS PRIOR TO ANTIRETROVIRAL THERAPY INITIATION: THE STRATEGIC TIMING OF ANTIRETROVIRAL TREATMENT (START} HIV RESERVOIR STUDY. - (08/11/21)   Early treated individuals had lower reservoir size, lower viral diversity and higher susceptibility to bNAbs Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infection - (08/11/21)   Switch to INSTI more than offset negative effects of weight gain on incidence of insulin resistance in people living with HIV - (08/09/21)   Combination of high liver and visceral fat predict diabetes in people living with HIV - (08/09/21)   The association of coronary calcification with visceral adiposity in people living with HIV. Results from the Liverpool multiparametric imaging collaboration - (08/06/21)   Prevalence and predictors of elevated arterial blood pressure in ageing people living with HIV attending care in Zambia - (08/06/21)   Sexual Minority Stress and Accelerated Cellular aging in Treated HIV Infection - (08/06/21)   Long-Acting Treatment & PrEP Key Studies at IAS 2021 - (08/04/21)   Immunoscenescence and HIV: mutual interactions? - (07/26/21)   Poor sleep quality in people with HIV linked to lower CSF amyloid beta 42 - (07/26/21)   HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/26/21)   Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/26/21)   HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/26/21)   Aging PLWH & Higher Readmission Hospital Rates than the General Population Hospital Readmissions Fall in Big HIV Group But Still High vs Non-HIV Patients - Mark Mascolini (07/23/21)   Good Adherence to Vaginal Ring and Daily PrEP in Half of Young African Women - Mark Mascolini (07/23/21)   Improving Hormone Levels in Transgenders Receiving Hormone Therapy - Mark Mascolini (07/23/21)   Fostemsavir Serious Adverse Events More Frequent in People Over 50, Men, North Americans - Mark Mascolini (07/23/21)   Integrase strand transfer inhibitor (INSTI) use and cancer incidence - Mark Mascolini (07/23/21)   Trichloroacetic Acid an Alternative to Electrocautery for Anal Cancer Precursor? - Mark Mascolini (07/23/21)   US MSM Seem Eager for Injectable PrEP-Side Effects, Cost Biggest Concerns - Mark Mascolini (07/23/21)   Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials - (07/22/21)   Long-acting Capsid Inhibitor Effective as PrEP Against Vaginal SHIV Transmission in Macaques - (07/22/21)   Barriers to Expanding PrEP Uptake among cis-gender African American Women in the US South - (07/22/21)   Understanding participant experiences and preferences in an injectable PrEP trial: A qualitative substudy of barriers, facilitators, and preferences for PrEP use among MSM and TGW - (07/22/21)   CLINICAL IMPACT OF ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (07/22/21)   LONG-TERM (96-WEEK) SAFETY OF FOSTEMSAVIR (FTR) IN HEAVILY TREATMENT-EXPERIENCED (HTE) ADULTS INFECTED WITH MULTIDRUG-RESISTANT (MDR) HIV-1 (BRIGHTE PHASE 3 STUDY) - (07/22/21)   Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks Islatravir/Doravirine Adverse Events Less Frequent in Second Half of 96-Week Trial - Mark Mascolini (07/22/21)   High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide online sample of United States men who have sex with men, 2019 - (07/22/21)   Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis - (07/22/21)   Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US - Online Survey - (07/22/21)   Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks - (07/22/21)   Safety and Pharmacokinetics of Oral Islatravir Once Monthly for HIV Pre-exposure Prophylaxis (PrEP): Week 24 Analysis of a Phase 2a Trial - (07/22/21)   Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform - (07/22/21)   Unsuppressed plasma HIV-RNA is associated with worse COVID-19 outcomes among people living with HIV. - (07/22/21)   The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study - (07/21/21)   The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)   Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV - (07/21/21)   Higher comorbidity and comedication burden in women and young people living with HIV More Comorbidities, Polypharmacy With HIV-But Subgroup Differences Abound - (07/21/21)   Mitochondrial disorders in activated memory CD4+ T cells derived from HIV-infected immunological non-responders - (07/21/21)   Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)   Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020. - (07/21/21)   Outcomes of Participants Switching from F/TDF to F/TAF for PrEP: Week 48 Results from the DISCOVER Open Label Phase - (07/21/21)   Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up - (07/21/21)   Sub-40-Copy Virologic Hints May Favor DTG/3TC Over Multidrug Combos in TANGO - Mark Mascolini (07/21/21)   Only 1 More Virologic Failure on CAB + RPV in Weeks 96 to 124 of FLAIR - Mark Mascolini - (07/21/21)   CAB + RPV Failure Risk Factor in 10% of Large French Cohort - Mark Mascolini - (07/21/21)   Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)   Impact of HIV on COVID-19 Outcomes among Hospitalized Adults in the U.S. - (07/21/21)   Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 - (07/21/21)   WEEK 124 OF THE RANDOMIZED, OPEN-LABEL, PHASE 3 FLAIR STUDY EVALUATING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR TREATMENT IN ADULTS WITH HIV-1 INFECTION - (07/21/21)   Low Proportion of Individuals Develop Metabolic Syndrome (MetS) or Hepatic Fibrosis After Switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed Patients: A Post Hoc Metabolic Analysis - (07/21/21)   Prevalence of genotypic baseline risk factors of Cabotegravir + Rilpivirine failure among ARV-naïve patients - (07/21/21)   Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) - (07/20/21)   CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS - (07/20/21)   CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA - (07/20/21)   CAB + RPV LA IMPLEMENTATION OUTCOMES AND ACCEPTABILITY OF MONTHLY CLINIC VISITS IMPROVED DURING COVID-19 PANDEMIC ACROSS US HEALTHCARE CLINICS (CUSTOMIZE: HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY) - (07/20/21)   Every-6-Month Lenacapavir With F/TAF Controls HIV Through 28 Weeks - Mark Mascolini (07/20/21)   Single-Pill DTG/3TC Effective in Suppressed People for 48 Weeks: SALSA - Mark Mascolini (07/20/21)   Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) - (07/20/21)   lntegrase strand transfer inhibitor (INSTI) use and cancer incidence - (07/20/21)   FEASIBILITY, EFFICACY, AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): 48-WEEK RESULTS OF THE STAT STUDY - (07/20/21)   SWITCHING TO THE 2-DRUG REGIMEN OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) FIXED-DOSE COMBINATION IS NON-INFERIOR TO CONTINUING A 3-DRUG REGIMEN THROUGH 48 WEEKS IN A RANDOMIZED CLINICAL TRIAL (SALSA) - (07/20/21)   COMPARISON OF VIRAL REPLICATION FOR THE 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) VERSUS A 3/4-DRUG TENOFOVIR ALAFENAMIDE-BASED REGIMEN (TBR) IN THE TANGO STUDY THROUGH WEEK 96 - (07/20/21)   Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDF - (07/20/21)   Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) with Preexisting Resistance and Viral Blips - (07/20/21)   Week 72 Outcomes and COVID-19 Impact From the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in Black American Adults With HIV - (07/20/21)   Higher comorbidity and co-medication burden in women and young people living with HIV - (07/20/21)   Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020 - Mark Mascolini (07/20/21)   METABOLIC HEALTH OUTCOMES AT WEEK 144 IN THE TANGO STUDY, COMPARING A SWITCH TO DTG/3TC VERSUS MAINTENANCE OF TAF-BASED REGIMENS - (07/20/21)   DTG + 3TC IN GEMINI-1 & -2: HIV-1 REPLICATION AT <50 C/ML AND VL 'BLIPS' THROUGH 144 WEEKS - (07/20/21)   Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial - (07/19/21)   The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: Results from the DRIVE-AHEAD clinical trial - (07/19/21)   Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine - (07/19/21)   SARS-CoV-2 Rate Similar in TDF PrEP Users and Matched No-TDF Controls - Mark Mascolini (07/19/21)   ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19 - (07/19/21)   ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs - (07/19/21)   ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 - (07/19/21)   Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults - (07/19/21)   New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - (07/19/21)   Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/12/21)   Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/12/21)   Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021 - (07/12/21)